Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)

Zoetis (ZTS) shares have declined to a multi-year low valuation, with a forward P/E of approximately 24, despite robust underlying fundamentals. The animal health market leader reported strong Q1 2025 operational growth across key product franchises, improved gross margins, and expanded market share, though international revenue was flat due to foreign exchange headwinds. The company continues to demonstrate consistent EBITDA and EPS growth, supported by aggressive share buybacks and a 3.2% shareholder yield. Zoetis is well-positioned for sustained growth, driven by a strong innovation pipeline, extensive patent protection, and secular tailwinds such as the deepening human-animal bond and aging pet population, with analysts projecting 15% EPS growth for FY2025.

Analysis

Zoetis (ZTS) is currently exhibiting a significant divergence between its market valuation and fundamental performance. The stock is trading at a multi-year low forward P/E ratio of approximately 24, a notable contraction from its historical premium, despite the company reinforcing its market leadership. The company's market share in the animal health sector has expanded to 28.1%, supported by consistent growth in revenue, EBITDA, and improving gross margins, which reached 83.2% in the U.S. in Q1 2025. While reported international revenue was flat, this was entirely due to foreign exchange headwinds masking robust 7% operational growth. This underlying strength is further evidenced by strong double-digit revenue growth in its key product franchises: the Simparica line grew 19%, dermatology products grew 10%, and the osteoarthritis pain franchise grew 15%. Management is actively enhancing shareholder value through aggressive share repurchases, contributing to a total shareholder yield of 3.2%, and has a 12-year track record of dividend increases. The company's durable competitive advantage is secured by extensive patent protection extending into the 2040s and sustained R&D investment, positioning it to capitalize on long-term secular tailwinds including the aging pet population and the deepening human-animal bond.

Key Decisions for Investors

• Given the stock's decline to a multi-year low valuation of approximately 24x forward P/E, investors may consider the current price a compelling entry point, as it appears disconnected from the company's strengthening fundamentals and market share gains.
• Investors should prioritize monitoring core operational metrics, particularly the 7% international operational growth and rising gross margins, rather than headline revenue figures recently suppressed by temporary foreign exchange headwinds.
• The total shareholder yield of 3.2%, driven by a 12-year high dividend yield and significant share buybacks, provides a tangible return floor and should be considered a key component of the total return thesis for ZTS.
• Continued double-digit growth in key franchises like Simparica, Apoquel/Cytopoint, and Librela/Solensia is a critical indicator to watch, as their performance validates the company's innovation pipeline and justifies a premium valuation over the long term.